Tucidinostat shows potent antitumor activity and inhibits several human-derived tumour cell lines, such as HL-60, U2OS, LNCaP with GI50s of 0.4 ± 0.1, 2.0 ± 0.6, and 4.0 ± 1.2 μM, respectively. In addition, Tucidinostat shows less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCCHEL)[1].

Tucidinostat (12.5-50 mg/kg, p.o.) dose-dependently reduces tumour size and tumour weight in mice bearing HCT-8 colorectal carcinoma, A549 lung carcinoma, BEL-7402 liver carcinoma, and MCF-7 breast carcinoma, and with no obvious body loss[1].

1616493-44-7

C22H19FN4O2

390.418

Chidamide;西达本胺;HBI-8000;CS 055

DMSO:50 mg/mL
H2O:Insoluble
Ethanol:1 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years